ACE2: The Major Cell Entry Receptor for SARS-CoV-2.

Area of Science:

• Virology and Molecular Biology
• Immunology and Inflammation
• Cardiovascular Physiology

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, has led to millions of infections and deaths globally.
• Individual susceptibility to severe COVID-19 and mortality remains incompletely understood.
• The angiotensin-converting enzyme 2 (ACE2) is a key receptor for SARS-CoV-2 cell entry.

Purpose of the Study:

• To elucidate the biological functions of ACE2, including its expression and regulation.
• To investigate the role of soluble ACE2 in COVID-19 disease progression and its therapeutic potential.
• To explore the impact of SARS-CoV-2 binding to ACE2 on the renin-angiotensin and kinin-kallikrein systems.

Main Methods:

• Review of existing literature on ACE2 biology, SARS-CoV-2 infection mechanisms, and related physiological systems.
• Analysis of the interplay between SARS-CoV-2, ACE2, and the renin-angiotensin system.
• Discussion of ACE2's involvement in regulating bradykinin and its implications for coagulation and inflammation.

Main Results:

• ACE2's expression and post-translational modifications influence SARS-CoV-2 cell entry.
• Soluble ACE2 levels may correlate with COVID-19 severity and represent a therapeutic target.
• SARS-CoV-2/ACE2 interaction disrupts the renin-angiotensin system and affects kinin-kallikrein pathways, impacting inflammation and coagulation.

Conclusions:

• A comprehensive understanding of ACE2's multifaceted roles is essential for developing effective COVID-19 therapies and diagnostics.
• Targeting ACE2 or its related pathways offers potential therapeutic strategies for managing COVID-19.
• Further research into ACE2's regulation of coagulation and inflammation is critical for assessing SARS-CoV-2's systemic impact.